"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
TOKYO and CAMBRIDGE, Mass., August 13, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.
2024年8月13日,日本东京的药企Eisai株式会社(CEO:内藤晴雄)和美国生物技术公司Biogen Inc.(纳斯达克股票代码:BIIb,总部位于马萨诸塞州剑桥,CEO:Christopher A. Viehbacher)今天宣布,阿联酋卫生和预防部已批准抗人化可溶性聚集的淀粉样蛋白β单克隆抗体LEQEMBI(lecanemab)用于治疗阿尔茨海默病(AD),包括轻度认知障碍(MCI)或疾病的轻度痴呆阶段(统称为早期AD)患者。LEQEMBI可选择性结合可溶性Aβ聚集体(原纤维*),以及Aβ斑块的主要组成部分不溶性Aβ聚集体(纤维),从而降低大脑中的Aβ原纤维和Aβ斑块。LEQEMBI是首个经批准的治疗药物,证明其通过这种机制降低疾病进展的速度,减缓认知和功能衰退。LEQEMBI还在美国、日本、中国、韩国、香港和以色列获得批准,并在美国、日本和中国销售。
LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel, and is being marketed in the U.S., Japan, and China.
LEQEMBI可选择性结合可溶性Aβ聚集体(原纤维*),以及Aβ斑块的主要组成部分不溶性Aβ聚集体(纤维),从而降低大脑中的Aβ原纤维和Aβ斑块。LEQEMBI是首个经批准的治疗药物,证明其通过这种机制降低疾病进展的速度,减缓认知和功能衰退。LEQEMBI还在美国、日本、中国、韩国、香港和以色列获得批准,并在美国、日本和中国销售。
LEQEMBI's approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 In the UAE, it is reported that 4.09% of those over 60 years old have dementia.3 AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.4
LEQEMBI得到许可是基于大型全球第三期Clarity AD研究。在Clarity AD研究中,LEQEMBI达到了其主要和所有关键的次要终点,其结果有统计学显著性1,2 。据报道,在阿联酋,60岁以上人群中有4.09%的人患有痴呆症。3 AD被认为是痴呆症的最常见原因,通常占病例的60-70%。4 Eisai在全球范围内负责lecanemab的开发和监管提交,Eisai和Biogen共同销售和推广该产品,Eisai具有最终决策权。Biogen在阿联酋开展LEQEMBI的商业化。
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Biogen will commercialize LEQEMBI in the UAE.
Eisai在全球范围内负责lecanemab的开发和监管提交,Eisai和Biogen共同销售和推广该产品,Eisai具有最终决策权。
* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.5 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.6
* 原纤维被认为是导致AD的脑损伤的原因之一,并被认为是Aβ最有毒的形式,在这种进行性的、令人沮丧的情况下,原纤维起着认知衰退的主要作用。原纤维通过多种机制对大脑中的神经元造成损害,从而可能对认知功能产生负面影响,不仅增加不溶性Aβ斑块的发展,而且增加对脑细胞膜以及传递神经细胞信号或神经细胞和其他细胞之间连接的直接损伤。减少原纤维可能通过降低大脑中的神经元损伤和认知功能障碍预防AD的进展。6
MEDIA CONTACTS |
|
Eisai Co., Ltd. Public Relations Department TEL : +81 (0)3-3817-5120 |
Biogen Inc. Jack Cox + 1-781-464-3260 public.affairs@biogen.com |
INVESTOR CONTACTS |
|
Eisai Co., Ltd. Investor Relations Department TEL: +81 (0) 3-3817-5122 |
Biogen Inc. Chuck Triano + 1-781-464-2442 IR@biogen.com |
媒体联系方式 |
|
英塞尔制药株式会社 公共关系部 TEL : +81 (0)3-3817-5120 |
渤健公司。 杰克·考克斯 + 1-781-464-3260 public.affairs@biogen.com |
投资者联系方式 |
|
英塞尔制药株式会社 投资者关系部门 TEL: +81 (0) 3-3817-5122 |
渤健公司。 查克·泰利亚诺 + 1-781-464-2442 IR@biogen.com |
Notes to Editors
爱立信的5G网络基础设施产品组合包括
- About lecanemab (LEQEMBI)
- 关于lecanemab(LEQEMBI)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
Lecanemab是Eisai和BioArctic战略研究联盟的成果,它是一种针对聚集的可溶性(原纤维)和不溶性淀粉样蛋白β(Aβ)的人源免疫球蛋白γ1(IgG1)单克隆抗体。
LEQEMBI's FDA approval was based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with LEQEMBI and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the LEQEMBI group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the LEQEMBI group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.
LEQEMBI的FDA批准基于Eisai的全球Clarity AD临床试验的第三期数据,在该试验中,它达到了主要终点和所有关键次要终点,其结果有统计学显著性1,2 。主要终点是全球认知和功能评分临床痴呆评级总分(CDR-SB)。在Clarity AD临床试验中,LEQEMBI治疗组18个月时较安慰剂组CDR-Sb的临床下降率减少了27%。基线时,两组患者的平均CDR-Sb评分约为3.2。在18个月时,LEQEMBI的调整最小二乘均值变化为1.21,安慰剂的为1.66(差异,-0.45;95%置信区间[CI],-0.67到-0.23;P10%)是输注反应、脑淀粉样蛋白免疫相关性脑血管淤血(ARIA-H,包括脑微出血、脑宏出血和表面性铁沉),脑水肿/渗出(ARIA-E),头痛和跌倒。
LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong and Israel for the treatment of MCI due to AD and mild AD dementia. Eisai has also submitted applications for approval of LEQEMBI in 11 countries and regions. A supplemental Biologics License Application (sBLA) for intravenous maintenance dosing was submitted to the U.S. Food and Drug Administration (FDA) in March 2024, which was accepted in June 2024. The rolling submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was initiated in the U.S. under Fast Track status in May 2024.
LEQEMBI已在美国、日本、中国、韩国、香港和以色列获批用于治疗由AD引起的轻度MCI和轻度AD痴呆。Eisai还提交了LEQEMBI在11个国家和地区的批准申请。3月2024年,美国食品和药品管理局(FDA)接受了静脉注射维持剂量的补充生物制品许可申请(sBLA),6月2024年批准。正在美国以快速通道状态下开展的皮下注射制剂维持剂量生物制品许可申请(BLA)的滚动提交,旨在开发提高患者便利性的缩短时间。
Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.
自2020年7月以来,面向临床正常且脑内淀粉样蛋白中间或高水平者的III期临床研究(AHEAD 3-45)正在进行中。AHEAD 3-45作为阿尔茨海默病临床试验贡献部门的公共-私营伙伴关系进行,该部门由美国国立老龄化研究所资助,致力于提供相关痴呆症的学术临床试验的优质基础设施,Eisai和Biogen。自2022年1月以来,组织遗传性AD的Tau NexGen临床研究(DIAD)由组织遗传性阿尔茨海默网络试验组(DIAN-TU)领导的进行,该网络由圣路易斯华盛顿大学医学院进行,包括lecanemab作为主干抗淀粉样蛋白疗法。
- About the Collaboration between Eisai and Biogen for AD
- 关于Eisai和Biogen在AD方面的合作
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
自2014年以来,Eisai和Biogen一直在合作开发和商业化AD治疗方案。Eisai在全球范围内负责lecanemab的开发和监管提交,Eisai和Biogen共同销售和推广该产品,Eisai具有最终决策权。
- About the Collaboration between Eisai and BioArctic for AD
- 关于Eisai和BioArctic在阿尔茨海默病方面的合作
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.
Eisai在阿尔茨海默病治疗上与BioArctic长期合作自2005年以来合作。Eisai已在2007年12月与BioArctic签订了协议,获得了研究、开发、生产和销售lecanemab治疗AD的全球权利。2015年5月,双方签订了有关抗体lecanemab备份的开发和商业化协议。
- About Eisai Co., Ltd.
- 关于Eisai株式会社
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Eisai的企业理念是“优先考虑患者和在日常生活领域中的人,并增加医疗保健所提供的福利。”在这个概念(也称为人类健康医疗概念)下,我们旨在有效地实现社会公益,缓解人们对健康的焦虑,减少健康差距。凭借全球的研发设施、制造基地和营销子公司网络,我们致力于创建和传递面向具有高未满足医学需求疾病的创新产品,特别关注我们的战略领域——神经学和肿瘤学。此外,我们通过与全球合作伙伴一起进行各种活动来证明我们消除被忽视的热带疾病的承诺。消除被忽视的热带疾病是联合国可持续发展目标(SDGs)之一。
In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
此外,我们通过与全球合作伙伴一起进行各种活动,证明了消除被忽视的热带疾病的承诺。
For more information about Eisai, please visit (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).
欲了解更多关于 Eisai 的信息,请访问全球总部网站:Eisai. Co., Ltd.、美国总部网站:Eisai, Inc. 或欧洲、中东、非洲、俄罗斯、澳大利亚和新西兰总部网站:Eisai Europe Ltd.,并在X(全球和美国)、领英(全球、美国和欧洲、中东和非洲)以及Facebook(全球)上与我们联系。
- About Biogen
- 关于渤健公司 渤健公司是一家成立于1978年的全球生物技术公司,开创了多个突破性创新,包括治疗多发性硬化的广泛药物组合、治疗脊髓性肌萎缩的首个获批治疗方法,以及两种共同开发的治疗阿尔茨海默病的方法。渤健公司正在推进可能的创新疗法,涉及神经学、神经精神病学、特殊免疫学和罕见疾病,并在强调其服务于人类并通过科学推进更健康、更可持续、更公平的世界的目的下保持高度集中。 我们会定期在我们的网站上发布可能对投资者重要的信息,在社交媒体上关注我们——Twitter、LinkedIn、Facebook、YouTube。 渤健公司安全港口: 本新闻稿包含前瞻性声明,涉及:我们的策略和计划;商业业务和管道计划的潜力和期望;资本配置和投资策略;临床开发计划、临床试验、数据宣读和呈现;监管讨论、提交、申报和批准;我们和我们的合作伙伴的产品和调查疗法的潜在好处、安全性和功效;投资、优化成本结构、改善风险配置和研产品线生产率的措施、合作和业务发展活动的潜在收益和可能;我们未来的财务和营运结果;2023年财务指引。这些前瞻性的声明可能会伴随着这样的话语:‘aim’、‘anticipate’、‘believe’、‘could’、‘estimate’、‘expect’、‘forecast’、‘goal’、‘intend’、‘may’、‘plan’、‘potential’、‘possible’、‘prospect’、‘will’、‘would’等类似含义的话语和术语。药物研发和商业化涉及高度的风险,只有少数的研究和开发项目会实现产品的商业化。早期临床试验的结果可能不具有全面结果或与后期或更大规模的临床试验和在其他潜在适应症中的试验的结果不具有预测性,并且不能保证其能够获得监管批准。您不应过度依赖这些声明。这些声明涉及风险和不确定性,可能导致实际结果与此类声明所反映的结果有所不同,包括:我们的产品销售依赖性;长期成功在发展、许可或收购其他产品候选或现有产品的其他适应症上的不确定性;在我们的产品市场上由于重要产品竞争而未能有效竞争;未能成功执行或实现我们的战略和增长举措的预期效益;在我们的产品中获得并维持足够的覆盖率、定价和赔付的困难;我们对开发、监管批准和商业化产品和业务的合作伙伴、合资伙伴和其他第三方的依赖,这些超出我们的控制范围;乌克兰冲突可能带来的潜在影响;与当前和潜在未来的医疗保健改革相关的风险;与商业化生物仿制药有关的风险;未能获得、保护和执行我们的数据、知识产权和其他专有权利以及相关的知识产权索赔和挑战的风险;在临床试验中取得积极结果,不保证在后续或确认性试验中重复,并不意味着早期临床试验中的成功能够在后续或大规模临床试验或其他潜在适应症的试验中预测出结果;与临床试验有关的风险,包括我们能否充分管理临床活动、额外数据或分析所产生的意外问题或监管机构可能需要额外信息或进一步研究,或可能无法通过批准或可能延迟批准我们的药物候选;不良安全事件发生,对我们的产品使用的限制,或产品责任索赔;与技术失灵或违规行为有关的风险;我们的制造过程出现问题的风险;与管理和人员变更有关的风险,包括吸引和保留员工;未能遵守法律法规的风险;在国际上开展业务的风险,包括货币汇率波动的风险;与我们的生产能力投资相关的风险;持续进行的COVID-19大流行对我们业务的直接和间接影响;与第三方销售和分销伪造或不适合的版本我们产品的风险;与社交媒体用于我们业务有关的风险;运营结果和财务状况;我们在物业投资方面的风险;与我们投资组合的市场、利率和信用风险有关;与我们股份回购计划有关的风险;与资本和信贷市场获得的风险有关;我们债务方面的风险;我们的合作协议中的控制变更规定;我们的有效税率波动风险;环境风险;和任何其他我们在U.S. Securities and Exchange Commission提交的其他报告中描述的风险和不确定性。这些声明仅适用于本新闻稿发布时。我们不承担公开更新任何前瞻性声明的任何义务。
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
成立于1978年的渤健公司是一家领先的生物技术公司,开创性地探索新的科学方法,以推进治疗方法的研发,以改善患者的生活质量,并创造与股东和社区共享的价值。我们深刻理解人体生物学,利用不同的治疗方式,推进世界一流的治疗方法和药物。我们的方法是勇敢冒险并平衡投资回报,以实现长期增长。
The company routinely posts information that may be important to investors on its website at . Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.
公司定期在其网站上发布投资者可能关注的信息。关注渤健公司的社交媒体——Facebook、领英、X、YouTube。
Biogen Safe Harbor
渤健公司免责声明
This news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.
此新闻发布包含关于Lecanemab的可能临床效果、Lecanemab的潜在益处、安全性和有效性、潜在的监管讨论、提交和批准以及时间等方面的前瞻性声明,以及有关治疗阿尔茨海默病的声明;关于渤健公司与英雄公司的合作安排的预期益处和潜力;渤健公司的商业和管线项目的潜力,包括Lecanemab;以及与制药和商业化相关的风险与不确定性。这些声明可能被识别为"目标"、"预测"、"认为"、"可能"、"估计"、"期望"、"预测"、"打算"、"可能"、"潜在"、"将"、"会"和其他具有相似含义的词语和术语。制药和商业化涉及高度的风险,只有少数研究和开发计划会导致产品的商业化。早期临床研究的结果可能并不表明完整结果或后期或更大规模的临床研究的结果,并不能确保其监管批准。不应过分依赖这些声明。
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.
这些声明涉及风险和不确定性,可能导致实际结果与这些声明反映的结果有所不同,包括但不限于在临床研究过程中出现的意外问题;出现不良安全事件的风险;意外的成本或延迟风险;其他意外障碍的风险;监管提交可能需要比预期更长的时间或更具挑战性;监管当局可能需要额外的信息或进一步的研究,或可能不能批准或可能延迟批准渤健公司的药物候选品(包括Lecanemab);专家委员会提交时间和内容的实际情况以及有关监管当局关于Lecanemab的决定,存在成功开发和潜在商业化Lecanemab的不确定性;未能保护和执行渤健公司的数据、知识产权和其他专有权利,以及与知识产权索赔和挑战相关的不确定性;产品责任索赔;和第三方合作风险。前述因素阐述了可能导致实际结果与渤健公司所期望的结果不符的许多因素,但不是所有因素。投资者应该考虑这个警告和风险因素,并参考渤健公司最近的年度或季度报告以及渤健公司向美国证券交易委员会提交的其他报告。这些声明仅反映本新闻发布日期的情况。渤健公司不承担任何公开更新前瞻性声明的义务。
References
参考
- Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at:
- van Dyck, H., et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;388:9-21. .
- Qassem T., et al, Prevalence and economic burden of dementia in the Arab world. BJPsych Open. 2023 Jul; 9(4): e126.
- World Health Organization. Dementia Fact Sheet. March 2023. Available at: .
- Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
- Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
- 英实制药公司在阿尔茨海默病临床试验(Clinical Trials on Alzheimer's Disease, CTAD)会议上展示了Lecanemab第三阶段确认性Clarity AD研究的全部结果。详情请参阅
- van Dyck H.,等。初期阶段的阿尔茨海默病lecanemab。新英格兰医学杂志。2023年;388:9-21。
- Qassem T.等人:阿拉伯世界痴呆症的患病率和经济负担。《BJPsych Open》。2023年7月;9(4):e126。
- 世界卫生组织。老年痴呆状况说明。Available at:。
- 阿密因L,哈里斯DA。Aβ受体专门识别纤维末端和神经毒性寡聚体。《自然通讯》Patent:2021年6月;12: 3451. DOI: 10.1038/s41467-021-23507-z。
- 小野幸雄、辻美蘭。Amyloid-β原纤维是阿尔茨海默病治疗的重要靶点。《国际分子科学》 2020 年 2 月;21(3):952。 doi:10.3390/ijms21030952。 PMID: 32023927;PMCID: PMC7037706。